BlackRock Boosts ImmunityBio Stake 29% to 34.08M Shares
IBRX has more than doubled off its 52-week low of $1.95 on elevated volume (3.1× avg).
Summary
BlackRock raised its ImmunityBio stake by 7.74M shares (29%) to 34.08M shares, worth about $298.4M, while Vanguard holds roughly 36.48M shares. Other institutions trimmed: D. E. Shaw sold ~1.02M shares, Morgan Stanley cut ~586K, Woodline down 28%, Voleon down 53%. The Q2 revenue figure of $50.7M (92% growth) is a rehash of results already reported in August, but the ownership shifts are new. Michael Caputo's appointment to Trump's Cancer Advisory Panel is flagged as a potential attention driver for Anktiva. Net institutional accumulation by the two largest holders is a modest positive, though the selling by others tempers the signal.
At the time of this announcement, IBRX was trading at $10.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.